Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy

Kim, Jihoon; Yung, Bryant C.; Kim, Won Jong; Chen, Xiaoyuan

doi:10.1016/j.jconrel.2016.12.026

Cited by 167 publications

(134 citation statements)

References 78 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…However, if the results of Allenbach and coworkers suggesting that the inducible NOS/nitric acid axis plays a role in the repair of damaged muscle in myositis patients are confirmed, this observation could be truly exciting with respect to new therapeutic strategies. Recent work by others suggesting that novel new strategies for therapeutically delivering nitrous oxide to damaged tissue in a clinical setting may be on the horizon (51)(52)(53).…”

Section: Further Perspective On the Studies Of Allenbach And Coworkersmentioning

confidence: 99%

MDA5 autoantibody—another indicator of clinical diversity in dermatomyositis

Sontheimer¹

2017

Annals of Translational Medicine

View full text Add to dashboard Cite

Allenbach and colleagues have recently reported for the first time the results of an intriguing study of the histopathologic, immunopathologic and gene expression differences in muscle biopsy tissue from adult dermatomyositis (DM) patients who do and do not have circulating MDA5 autoantibodies (anti-MDA5). Anti-MDA5 were originally identified in a clinically-defined subset of DM patients whose disease was expressed predominately in the skin for unusually long periods of time without accompanying muscle weakness [i.e., "clinically-amyopathic DM" (CADM)] and were at risk for acute, rapidly-progressive form of interstitial lung disease (ILD). As an academic dermatologist in the United States of America (USA) having a career-long interest in the CADM subset, I would like to share my perspective on the results of the work by Allenbach and colleagues and offer some suggestions for additional study in this area. But to do so most effectively, I first would like to review the clinical concept of CADM and its association with anti-MDA5 antibody production and a potentially-fatal form of (ILD).

show abstract

Section: Further Perspective On the Studies Of Allenbach And Coworkersmentioning

confidence: 99%

MDA5 autoantibody—another indicator of clinical diversity in dermatomyositis

Sontheimer¹

2017

Annals of Translational Medicine

View full text Add to dashboard Cite

show abstract

“…been reported that the clearance effect of NO by cancer cells is closely related to its concentration and release rate. [14] However, NO molecules feature a short half-life in vivo and is prone to react with bio-macromolecules and free radicals, so it is difficult for NO to achieve effective enrichment in tumor region. Therefore, developing external-responsive and local-triggered NO donors can be employed for on-demand NO release.…”

mentioning

confidence: 99%

Nanomedicine‐Enabled Photonic Thermogaseous Cancer Therapy

et al. 2019

View full text Add to dashboard Cite

Local photothermal hyperthermia for tumor ablation and specific stimuliresponsive gas therapy feature the merits of remote operation, noninvasive intervention, and in situ tumor‐specific activation in cancer‐therapeutic biomedicine. Inspired by synergistic/sequential therapeutic modality, herein a novel therapeutic modality is reported based on the construction of two‐dimensional (2D) core/shell‐structured Nb2C–MSNs–SNO composite nanosheets for photonic thermogaseous therapy. A phototriggered thermogas‐generating nanoreactor is designed via mesoporous silica layer coating on the surface of Nb2C MXene nanosheets, where the mesopores provide the reservoirs for NO donor (S‐nitrosothiol (RSNO)), and the core of Nb2C produces heat shock upon second near‐infrared biowindow (NIR‐II) laser irradiation. The Nb2C–MSNs–SNO‐enabled photonic thermogaseous therapy undergoes a sequential process of phototriggered heat production from the core of Nb2C and thermotriggered NO generation, together with photoacoustic‐imaging (PAI) guidance and monitoring. The constructed Nb2C–MSNs–SNO nanoreactors exhibit high‐NIR‐induced photothermal effect, intense NIR‐controlled NO release, and desirable PAI performance. Based on these unique theranostic properties of Nb2C–MSNs–SNO nanocomposites, sequential photonic thermogaseous therapy with limited systematic toxicity on efficiently suppressing tumor growth is achieved by PAI‐guided NIR‐controlled NO release as well as heat generation. Such a thermogaseous approach representes a stimuli‐selective strategy for synergistic/sequential cancer treatment.

show abstract

“…It has been reported that NO within the concentration range of 1 mm-1 mm can yield direct anticancer effects with few adverse effects,b ut higher concentrations (> 1mm)m ay cause NO poisoning. [12] Additionally,t he NO release rate is also avery important factor for the functions of NO.Although it is the generated NO concentration (rather than NO release rate) that may be an important determinant in whether NO can mediate the cancer cell death, [13] faster NO release will yield as tronger cancer cell-killing effect than slower NO release under the conditions of similar total NO concentrations.Overall, the functions of NO are closely associated with the NO-releasing characteristics/concentrations that can be determined by NO donors and the tumor microenvironment (TME). [12a] Therefore,s timuli-responsive NO donors are highly desired for releasing NO in ac ontrolled manner for on-demand cancer therapy with very little systemic toxicity.…”

Section: Introductionmentioning

confidence: 99%

Stimuli‐Responsive NO Release for On‐Demand Gas‐Sensitized Synergistic Cancer Therapy

2018

Self Cite

View full text Add to dashboard Cite

Featuring high biocompatibility, the emerging field of gas therapy has attracted extensive attention in the medical and scientific communities. Currently, considerable research has focused on the gasotransmitter nitric oxide (NO) owing to its unparalleled dual roles in directly killing cancer cells at high concentrations and cooperatively sensitizing cancer cells to other treatments for synergistic therapy. Of particular note, recent state-of-the-art studies have turned our attention to the chemical design of various endogenous/exogenous stimuli-responsive NO-releasing nanomedicines and their biomedical applications for on-demand NO-sensitized synergistic cancer therapy, which are discussed in this Minireview. Moreover, the potential challenges regarding NO gas therapy are also described, aiming to advance the development of NO nanomedicines as well as usher in new frontiers in this fertile research area.

show abstract

Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy

Cited by 167 publications

References 78 publications

MDA5 autoantibody—another indicator of clinical diversity in dermatomyositis

MDA5 autoantibody—another indicator of clinical diversity in dermatomyositis

Nanomedicine‐Enabled Photonic Thermogaseous Cancer Therapy

Stimuli‐Responsive NO Release for On‐Demand Gas‐Sensitized Synergistic Cancer Therapy

Contact Info

Product

Resources

About